| Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and … A Gupta, GM Mugundu, PB Desai, KE Thummel, JD Unadkat Drug metabolism and disposition 36 (6), 1172-1180, 2008 | 119 | 2008 |
| The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects J Tong, N Dave, GM Mugundu, HW Davis, BD Gaylinn, MO Thorner, ... European journal of endocrinology 168 (6), 821-828, 2013 | 103 | 2013 |
| A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma E Méndez, CP Rodriguez, MC Kao, S Raju, A Diab, RA Harbison, ... Clinical Cancer Research 24 (12), 2740-2748, 2018 | 101 | 2018 |
| A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. NH Segal, AK Gopal, S Bhatia, HE Kohrt, R Levy, MJ Pishvaian, R Houot, ... Journal of Clinical Oncology 32 (15_suppl), 3007-3007, 2014 | 74 | 2014 |
| Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. AT Shaw, TM Bauer, E Felip, B Besse, LP James, JS Clancy, G Mugundu, ... Journal of Clinical Oncology 33 (15_suppl), 8018-8018, 2015 | 55 | 2015 |
| A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous … EEW Cohen, KJ Harrington, DS Hong, R Mesia, I Brana, PP Segura, ... Annals of Oncology 29, viii372, 2018 | 42 | 2018 |
| Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors N Takebe, AR Naqash, G O'Sullivan Coyne, S Kummar, K Do, A Bruns, ... Clinical Cancer Research 27 (14), 3834-3844, 2021 | 40 | 2021 |
| A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors J Mateo, J Berlin, JS De Bono, RB Cohen, V Keedy, G Mugundu, L Zhang, ... Cancer chemotherapy and pharmacology 74, 1039-1046, 2014 | 39 | 2014 |
| Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study KN Moore, SK Chambers, EP Hamilton, L Chen, AM Oza, SA Ghamande, ... Clinical Cancer Research 28 (1), 36-44, 2022 | 38 | 2022 |
| A phase I study of PF-05082566 (anti-4-1BB)+ rituximab in patients with CD20+ NHL. AK Gopal, NL Bartlett, R Levy, R Houot, SD Smith, NH Segal, AD Thall, ... Journal of Clinical Oncology 33 (15_suppl), 3004-3004, 2015 | 31 | 2015 |
| Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ... Oncoimmunology 9 (1), 1748982, 2020 | 30 | 2020 |
| Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: dose escalation E Hamilton, GS Falchook, JS Wang, S Fu, A Oza, S Karen, ER Imedio, ... Cancer Res 79 (13 Suppl), CT025, 2019 | 26 | 2019 |
| Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. MR Patel, GS Falchook, JSZ Wang, E Rodrigo Imedio, S Kumar, ... Journal of Clinical Oncology 37 (15_suppl), 2562-2562, 2019 | 25 | 2019 |
| Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC‐MS/MS cocktail assays and RT‐PCR L Liu, GM Mugundu, BJ Kirby, D Samineni, PB Desai, JD Unadkat Biopharmaceutics & drug disposition 33 (4), 207-217, 2012 | 24 | 2012 |
| Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction by efavirenz in primary human hepatocytes GM Mugundu, N Hariparsad, PB Desai Drug metabolism letters 4 (1), 45-50, 2010 | 24 | 2010 |
| Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced … J Bendell, T Bauer, M Patel, G Falchook, JL Karlix, E Lim, G Mugundu, ... Cancer research 79 (13_Supplement), CT026-CT026, 2019 | 22 | 2019 |
| Evidence of immune activation in the first-in-human phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors J Bendell, T Bauer, M Patel, G Falchook, JL Karlix, E Lim, G Mugundu, ... Breast 2 (5), 33, 2019 | 22 | 2019 |
| Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies … EE Cohen, DS Hong, TW Draper, WN William, D Schrijvers, RM Nin, ... Annals of Oncology 28, v403, 2017 | 22 | 2017 |
| A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in … EA Lim, TM Bauer, MR Patel, GS Falchook, JL Karlix, JH Choe, ... J Clin Oncol 38 (5518), 10.1200, 2020 | 21 | 2020 |
| Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study. KN Moore, SK Chambers, EP Hamilton, L Chen, AM Oza, SA Ghamande, ... Journal of Clinical Oncology 37 (15_suppl), 5513-5513, 2019 | 20 | 2019 |
